[1]胡可纯,张强惠子,刘海飞,等.抗凝药物预防PICC导管相关性血栓形成的Meta分析[J].医学信息,2023,36(19):23-28.[doi:10.3969/j.issn.1006-1959.2023.19.006]
　HU Ke-chun,ZHANG Qiang-hui-zi,LIU Hai-fei,et al.Meta-analysis of Anticoagulant Drugs for Prevention of PICC Catheter-related Thrombosis[J].Journal of Medical Information,2023,36(19):23-28.[doi:10.3969/j.issn.1006-1959.2023.19.006]
点击复制

抗凝药物预防PICC导管相关性血栓形成的Meta分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年19期
页码:
23-28
栏目:
医学数据科学
出版日期:
2023-10-01

文章信息/Info

Title:
Meta-analysis of Anticoagulant Drugs for Prevention of PICC Catheter-related Thrombosis
文章编号:
1006-1959（2023）19-0023-06
作者:
胡可纯; 张强惠子; 刘海飞; 等
（1.首都医科大学护理学院，北京 100069；2.空军特色医学中心中医科，北京 100142；3.首都医科大学附属北京朝阳医院肿瘤科，北京 100020）
Author(s):
HU Ke-chun; ZHANG Qiang-hui-zi; LIU Hai-fei; et al.
(1.School of Nursing,Capital Medical University,Beijing 100069,China;2.Department of Traditional Chinese Medicine,Air Force Medical Center PLA,Beijing 100142,China;3.Department of Oncology,Beijing Chao-Yang Hospital,Capital Medical University,Beijing 100020,China)
关键词:
PICC; 血栓; 抗凝药物; 凝血功能
Keywords:
PICC; Thrombosis; Anticoagulant drugs; Blood coagulation function
分类号:
R472
DOI:
10.3969/j.issn.1006-1959.2023.19.006
文献标志码:
A
摘要:
目的 评价使用抗凝药物预防PICC-CRT的有效性及安全性，不同抗凝药物预防效果的优劣，为预防置管后PICC-CRT形成提供参考。方法 使用计算机检索2010-2022年PubMed、EMbase、Cochrane Library、Web of Science、Ovid、EBSCO、Elsevier、Wiley、中国学术期刊全文数据库、中国生物医学文摘数据库和万方数据库中有关抗凝药物预防PICC-CRT效果的随机对照试验。按照纳入、排除标准进行文献筛选，根据Cochrane Handbook偏倚风险工具对纳入文献进行质量评价。采用RevMan 5.3软件进行Meta分析。利用Stata软件进行网状Meta分析。结果 最终纳入8个RCTs，共1493例PICC置管患者。Meta分析显示，预防性使用抗凝药物可有效减少PICC置管患者导管相关性血栓发生率[OR=0.22，95%CI（0.13，0.36），P＜0.01]，对血小板、D-二聚体影响不明显，差异无统计学意义，OR值分别为[OR=-3.25，95%CI（-12.04，5.54），P＞0.01]、[OR=-0.02，95%CI（-0.04，0.00），P＞0.01]。抗凝药物带来的药物不良反应较少，差异无统计学意义[OR=1.83，95%CI（0.38，8.68），P＞0.01]。网状Meta分析显示：低分子肝素钠对PICC置管患者的血栓发生率的改善效果最佳，其次是低分子肝素钙、阿司匹林、利伐沙班。结论 抗凝药物可有效预防PICC-CRT，对PICC相关性血栓发生的高危人群推荐优先使用低分子肝素钠进行预防性抗凝。同时密切监测药物不良反应及血常规、凝血功能的变化。
Abstract:
Objective To evaluate the efficacy and safety of anticoagulants in preventing PICC-CRT, and the preventive effects of different anticoagulants, so as to provide reference for preventing the formation of PICC-CRT after catheterization.Methods PubMed, EMbase, Cochrane Library, Web of Science, Ovid, EBSCO, Elsevier, Wiley, China Academic Journal Full-text Database, China Biomedical Abstracts Database and Wanfang Database were searched by computer for randomized controlled trials on the effect of anticoagulant drugs in preventing PICC-CRT from 2010 to 2022. The literature was screened according to the inclusion and exclusion criteria, and the quality of the included literature was evaluated according to the Cochrane Handbook bias risk tool. Meta-analysis was performed using RevMan 5.3 software. Network meta-analysis was performed using Stata software.Results Finally, 8 RCTs were included, involving 1493 patients with PICC catheterization. Meta-analysis showed that prophylactic use of anticoagulants could effectively reduce the incidence of catheter-related thrombosis in patients with PICC [OR=0.22,95%CI(0.13,0.36),P<0.01], there was no significant effect on platelet and D-dimer, and the difference was not statistically significant, the OR values were [OR=-3.25,95%CI(-12.04,5.54),P>0.01], [OR=-0.02,95%CI(-0.04,0.00),P>0.01], respectively. The adverse drug reactions caused by anticoagulant drugs were less, and the difference was not statistically significant [OR=1.83,95%CI(0.38,8.68),P>0.01]. Network Meta-analysis showed that low molecular weight heparin sodium had the best effect on improving the incidence of thrombosis in patients with PICC catheterization, followed by low molecular weight heparin calcium, aspirin and rivaroxaban.Conclusion Anticoagulant drugs can effectively prevent PICC-CRT. Low molecular weight heparin sodium is recommended to prevent PICC-related thrombosis in high risk population. At the same time, the changes of adverse drug reactions, blood routine and coagulation function are closely monitored.

参考文献/References:

[1]Kang J,Sun W,Li H,et al.Validation of Michigan risk score and D-dimer to predict peripherally inserted central catheter-related thrombosis: A study of 206,132 catheter days[J].J Vasc Access,2022,23(5):764-769.[2]Chen P,Wan G,Zhu B.Incidence and risk factors of symptomatic thrombosis related to peripherally inserted central catheter in patients with lung cancer[J].J Adv Nurs,2021,77(3):1284-1292.[3]Fu J,Cai W,Zeng B,et al.Development and validation of a predictive model for peripherally inserted central catheter-related thrombosis in breast cancer patients based on artificial neural network: A prospective cohort study[J].Int J Nurs Stud,2022,135:104341.[4]Itkin M,Mondshein JI,Stavropoulos SW,et al.Peripherally inserted central catheter thrombosis--reverse tapered versus nontapered catheters: a randomized controlled study[J].J Vasc Interv Radiol,2014,25(1):85-91.[5]Ingram PR,Kilgarriff S,Grzelak M,et al.Risk factors for catheter related thrombosis during outpatient parenteral antimicrobial therapy[J].J Vasc Access,2022,23(5):738-742.[6]Skeik N,Westergard E.Recommendations for VTE Prophylaxis in Medically Ill Patients[J].Ann Vasc Dis,2020,13(1):38-44.[7]Young AM,Billingham LJ,Begum G,et al.Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial[J].Lancet,2009,373(9663):567-574.[8]Gonzalez-Porras JR,Mateo J,Gonzalez-Calle V,et al.Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH-SETH[J].Clin Transl Oncol,2022,24(5):770-783.[9]Lyman GH,Carrier M,Ay C,et al.American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer[J].Blood Adv,2021,5(4):927-974.[10]Higgins JP,Green S.Cochrane handbook for systematic reviews of intervention version 5.1.0[EB/OL].(2016-05-10)[2023-01-10].http://handbook.cochrane.org/.pdf.[11]闻曲,成芳,鲍爱琴,等.血液高凝恶性肿瘤患者PICC同步抗凝效果探讨[J].护理学杂志,2010,25(19):7-9.[12]李旭英,孙振球,谌永毅,等.阿司匹林对经外周静脉置入中心静脉导管相关性血栓的预防作用[J].中华临床营养杂志,2010(2):121-123.[13]陈燕,肖璐,张细梅,等.老年病人PICC置管后抗凝治疗预防上肢静脉血栓的疗效观察[J].护理研究,2014,28(31):3892-3894.[14]王宝娜,昝英,王利.小剂量阿司匹林口服对乳腺癌患者PICC置管后血栓预防的影响[J].中华现代护理志,2014,20(3):249-251.[15]夏宝国,李霞,刘小晨.拜阿司匹林在妇科恶性肿瘤PICC置管患者中的应用价值[J].中国医刊,2018,53(10):1172-1175.[16]张娟,李英,王雪姣.乳腺癌化疗后PICC置管应用低分子肝素钙的效果及对其深静脉血栓发生几率的影响[J].中国急救医学,2018,38(10):161.[17]蔡李芬,朱晓萍.低分子肝素钙用于乳腺癌术后静脉血栓预防效果观察[J].浙江医学,2021,43(4):414-416,419.[18]Ikesaka R,Siegal D,Mallick R,et al.Canadian Venous Thromboembolism Research Network (CanVECTOR). Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM-Line): A two-center open-label pilot randomized controlled trial[J].Res Pract Thromb Haemost,2021,5(4):e12517.[19]Key NS,Khorana AA,Kuderer NM,et al.Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update[J].J Clin Oncol,2020,38(5):496-520.[20]NCCN.NCCN Guideline on Cancer-Associated Venous Thromboembolic Disease.Version 1[M/OL].(2020-04-16)[2023-01-06].https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf.[21]植艳茹,李海燕,陆清声.住院患者静脉血栓栓塞症预防护理与管理专家共识[J].解放军护理杂志,2021,38(6):17-21.[22]于峰，李美杰，陈玉.低分子肝素钠联合双下肢气压泵在子宫脱垂患者术后预防下肢静脉血栓中的应用价值[J].血管与腔内血管外科杂志,2022,8(5):617-620.[23]莫智媛.低分子肝素钠联合气压治疗在预防妇科肿瘤术后下肢深静脉血栓(DVT)的临床效果和应用价值[J].现代预防医学,2020,47(14):2681-2684.[24]马玉琴,李亚琴,李美琴,等.低分子肝素钠预防妇科肿瘤围手术期下肢深静脉血栓的疗效与安全性[J].中国计划生育和妇产科,2019,10(11):43-46.[25]刘琳,朱红江,刘明阳,等.低分子肝素联合尿激酶治疗下肢深静脉血栓的有效性及对生活质量的影响[J].中国临床保健杂志,2022,25(1):82-85.[26]白雪,宋瑾,林雪,等.利伐沙班预防乳腺癌经外周置入中心静脉导管相关性血栓效果观察[J].人民军医,2020,63(12):1201-1204.

相似文献/References:

[1]曾 频,雷佳芳,刘晓姝,等.基于词频分析透视近十年国内PICC研究[J].医学信息,2019,32(03):19.[doi:10.3969/j.issn.1006-1959.2019.03.007]
　ZENG Pin,LEI Jia-fang,LIU Xiao-shu,et al.Perspective of Domestic PICC Research in the Past Ten Years Based on Word Frequency Analysis[J].Journal of Medical Information,2019,32(19):19.[doi:10.3969/j.issn.1006-1959.2019.03.007]
[2]卞丛燕,徐卫亭,古小松.肺动脉高压的血栓栓塞的机制[J].医学信息,2019,32(09):25.[doi:10.3969/j.issn.1006-1959.2019.09.009]
　BIAN Cong-yan,XU Wei-ting,GU Xiao-song.Mechanism of Thromboembolism in Pulmonary Arterial Hypertension[J].Journal of Medical Information,2019,32(19):25.[doi:10.3969/j.issn.1006-1959.2019.09.009]
[3]姚 薇,倪慧珏.应用“康复助手”在PICC置管患者延续护理中 自我管理能力的影响[J].医学信息,2019,32(16):178.[doi:10.3969/j.issn.1006-1959.2019.16.061]
　YAO Wei,NI Hui-jue.Application of "Rehabilitation Assistant" in PICC to Manage the Influence of Self-management Ability in Patients' Continuous Care[J].Journal of Medical Information,2019,32(19):178.[doi:10.3969/j.issn.1006-1959.2019.16.061]
[4]黄冬琴,吴 蔓.不同剂量尿激酶经导管溶栓治疗下肢深静脉血栓形成的疗效[J].医学信息,2020,33(10):122.[doi:10.3969/j.issn.1006-1959.2020.10.034]
　HUANG Dong-qin,WU Man.Therapeutic Effect of Different Doses of Urokinase via Catheter Thrombolysis on Lower Limb Deep Vein Thrombosis[J].Journal of Medical Information,2020,33(19):122.[doi:10.3969/j.issn.1006-1959.2020.10.034]
[5]昝双江,于智杰,李海燕.抗血小板药物在急性心肌梗死治疗中的应用[J].医学信息,2020,33(12):33.[doi:10.3969/j.issn.1006-1959.2020.12.011]
　ZAN Shuang-jiang,YU Zhi-jie,LI Hai-yan.Application of Antiplatelet Drugs in the Treatment of Acute Myocardial Infarction[J].Journal of Medical Information,2020,33(19):33.[doi:10.3969/j.issn.1006-1959.2020.12.011]
[6]王金旋.居家维护模式在PICC带管肿瘤出院患者中的安全性和有效性研究[J].医学信息,2021,34(18):187.[doi:10.3969/j.issn.1006-1959.2021.18.052]
　WANG Jin-xuan.Study on the Safety and Effectiveness of Home Maintenance Mode inPICC Tumor Discharged Patients[J].Journal of Medical Information,2021,34(19):187.[doi:10.3969/j.issn.1006-1959.2021.18.052]
[7]孙 静,仲丹丹,李立平,等.静脉治疗护理小组在持续改进PICC护理质量中的应用及对患者生活质量的影响[J].医学信息,2021,34(24):190.[doi:10.3969/j.issn.1006-1959.2021.24.052]
　SUN Jing,ZHONG Dan-dan,LI Li-ping,et al.Application of Intravenous Treatment Nursing Group in Continuous Improvement of PICC Nursing Quality and its Effect on Quality of Life[J].Journal of Medical Information,2021,34(19):190.[doi:10.3969/j.issn.1006-1959.2021.24.052]
[8]傅建玲,夏艳秋,李 安,等.基于HIS系统的随访管理平台在PICC带管出院患者导管维护中的应用[J].医学信息,2022,35(05):181.[doi:10.3969/j.issn.1006-1959.2022.05.049]
　FU Jian-ling,XIA Yan-qiu,LI An,et al.Application of Follow-up Management Platform Based on HIS System in PICC Catheter Maintenance for Discharged Patients[J].Journal of Medical Information,2022,35(19):181.[doi:10.3969/j.issn.1006-1959.2022.05.049]
[9]邹光美,黄朝任.白介素6基因多态性与多种疾病的相关性研究[J].医学信息,2022,35(12):61.[doi:10.3969/j.issn.1006-1959.2022.12.014]
　ZOU Guang-mei,HUANG Chao-ren.Correlation Between Interleukin 6 Gene Polymorphism and Various Diseases[J].Journal of Medical Information,2022,35(19):61.[doi:10.3969/j.issn.1006-1959.2022.12.014]
[10]廖卫娇.彩色多普勒超声评估透析患者动静脉内瘘血栓及狭窄的临床价值[J].医学信息,2022,35(24):145.[doi:10.3969/j.issn.1006-1959.2022.24.031]
　LIAO Wei-jiao.Clinical Value of Color Doppler Ultrasound in Evaluating Arteriovenous Fistula Thrombosis and Stenosis in Dialysis Patients[J].Journal of Medical Information,2022,35(19):145.[doi:10.3969/j.issn.1006-1959.2022.24.031]

更新日期/Last Update: 1900-01-01